Pazopanib (10), sorafenib (11), regorafenib (12, 13), anlotinib (14) and lenvatinib (15), which all have activity against VEGFR, PDGFR, c-KIT, FGFR and RET, and cabozantinib (16), which targets VEGFR, MET, AXL and RET, have all shown some clinical efficacy in OS and ES patients. Here, AXL is linked to Ewing sarcoma.